←
OpenSource Cardiology89 posts
OpenSource Cardiology avatar

OpenSource Cardiology

@opensourcecards

OpenSource Cardiology is a physician-led, open access, peer reviewed journal designed for physicians, authors, reviewers, and scientists.

◷ Joined June 2026▧ 35 Photos and videos
OpenSource Cardiology avatar
OpenSource Cardiology@opensourcecards·Jul 31

Broader access. Open access. No paywalls. Physician-led. Nonprofit. Author incentives. Reviewer incentives. Fair and timely reviews. A system that works for us. Not them. Follow us. Submit your manuscript. Sign up as a reviewer. @opensourcecards

0:43
OpenSource Cardiology avatar
OpenSource Cardiology@opensourcecards·8h

🆕 in OpenSource: Cardiology Explanted hearts with amyloidosis continue beating, oftentimes for up to 30 minutes after they are removed. In this Imaging Pearl, @BrettSperryMD and Jessica Heimes describe a patient with AL cardiac amyloidosis who had achieved complete hematologic response within 3 months on cyclophosphamide, bortezomib, dexamethasone and daratumumab. End-stage heart failure symptoms and recurrent pleural effusions persisted, and he underwent heart transplantation. A typical explanted heart with a dilated cardiomyopathy has minimal or no agonal contractions and quickly becomes soft and pliable. Amyloid hearts permanently retain their native three-dimensional shape because of extensive fibrosis and amyloid fibril infiltration in all cardiac chambers. With their high ventricular mass, agonal contractions can be noted for quite some time after explant. Early diagnosis of cardiac amyloidosis is essential to avoid these irreversible structural changes. opensourcecardiology.org/doi… Free to read, no paywalls

Post attachment
0:21
OpenSource Cardiology avatar
OpenSource Cardiology@opensourcecards·Nov 16

🆕 in OpenSource: Cardiology Should prasugrel replace ticagrelor as the default after PCI for ACS? And can it let you drop aspirin at primary PCI? Two trials presented at ESC Congress 2026 and published in NEJM tested these questions. @DrHBulluck and @DLBhattMD conclude that the trials support neither a universal prasugrel default nor this specific immediate aspirin-free strategy. • SWITCH-SWEDEHEART: a prasugrel-default policy did not significantly reduce 1-year death, MI or stroke (adjusted OR 0.90, 95% CI 0.77–1.06). Only 60.6% received prasugrel under the prasugrel default, vs 75.8% receiving ticagrelor under the ticagrelor default. • PREMIUM: omitting aspirin with reduced-dose prasugrel at primary PCI in STEMI failed non-inferiority (HR 1.34, 95% CI 1.02–1.75), despite lower bleeding. Either generic prasugrel or generic ticagrelor remains a reasonable choice for many ACS patients after PCI. Stopping aspirin after an uneventful first month is supported by randomized and meta-analytic evidence. opensourcecardiology.org/doi… Free to read, no paywalls

Post attachmentPost attachment
OpenSource Cardiology avatar
OpenSource Cardiology@opensourcecards·Nov 7

This is true! But it is also: 1. Unpaid labor that for-profit journals extract while charging authors thousands in APCs 2. Almost never recognized in a way that actually helps careers or promotion 3. Slow and high-friction, with weak incentives for timely or high-quality reviews 4. Buried in a system that makes science hard and expensive to publish and read 5. Done without real compensation, credit, or advancement pathways for the reviewers who do the work Which is exactly what OpenSource: Cardiology is built to fix @jtsaxon @BrettSperryMD

Peer review is: 1. Fun 2. A way to learn methods 3. A sneak peak at the future 4. A chance to shape the field 5. Community service 6. A way to become known for your expertise My feed - for some reason - has endless complaints about peer review, requests for payment, etc

OpenSource Cardiology avatar
OpenSource Cardiology@opensourcecards·Nov 5

At a lower-volume center where one operator did 146 septal myectomies, in-hospital mortality was 0.7%, comparable to the highest-volume group in a national study. A single-operator model may build expertise closer to patients far from high-volume centers.

1:12
OpenSource Cardiology avatar
OpenSource Cardiology@opensourcecards·Nov 2

On the bench, 20 of 21 Onyx coronary stents (2–5 mm) fractured on 6–10 mm high-pressure balloons, most linearly (16/20), and smaller stents needed higher balloon-to-stent ratios. Important when managing stents in infants whose vessels will outgrow them.

1:19
Ahmad Masri avatar
⟳ OpenSource Cardiology retweeted
Ahmad Masri@MasriAhmadMD·Oct 28

The devil is in the details. Even if both trials have positive primaries, ACACIA-HCM Had 10% reduced LVEF (most were managed just by downtitration similar to what you do in hypertension or what happened with sacubitril/valsartan), only 3% had to hold their dose, when 80% of patients were on max doses 15-20 mg within 8 weeks. ODYSSEY had 20%+ low lvef, everyone had to hold drug due to its pk/pd, and 50% were on high doses only, and had many months to do that. We will also get a wealth of data from FOREST HCM- a strategy of protocol and clinician driven titration. Regardless of efficacy, if you have access to both, how can you as a clinician justify reaching for a drug with a significantly worse safety profile? We see the same double rate of LVEF reduction in oHCM as well. In a patient-centered environment, I cannot see an argument for this. Safety in HCM is being marginalized in discussions that compare different therapeutic approaches. This is not what you observe typically in drug development or use -->safety first. From an efficacy perspective, there are many other time points including EOT that shows you a KCCQ difference it 5+, +NYHA class, and +Ve/VCO2. The positive primary in a small sample size is a gateway to assess the rest of your relevant endpoints in a complex heterogeneous population. One cannot put the blinders on in this scenario unless there is an argument for a bias in endpoint assessment, which isnt the case. The trial and KCCQ assessments were the same throughout. The placebo arm had fluctuations in their response. #CardioTwitter

🆕 in OpenSource: Cardiology ACACIA-HCM After ODYSSEY-HCM: Different Verdicts, Similar Signals One myosin-inhibitor trial in nonobstructive HCM was positive and the other was not, but the placebo-corrected effects were close: KCCQ-CSS • ODYSSEY-HCM (mavacamten): +2.7 points (95% CI −0.1 to 5.6; p=0.06) • ACACIA-HCM (aficamten): +3.0 points (95% CI 0.5 to 5.5; p=0.02) Peak VO₂ • ODYSSEY-HCM: +0.47 mL/kg/min (95% CI −0.03 to 0.98; p=0.07) • ACACIA-HCM: +0.67 mL/kg/min (95% CI 0.22 to 1.11; p=0.003) Both trials assumed a 5-point KCCQ-CSS effect, larger than either one observed. @AlbertoAimo90, @PanicellaG and @IacopoOlivotto show the contrast is sharper in the statistical verdict than in the observed efficacy. Their reading is a real but heterogeneous benefit: modest on average, potentially meaningful in selected patients, and offset by a need for structured LVEF monitoring. opensourcecardiology.org/doi… Free to read, no paywalls

Post attachment
OpenSource Cardiology avatar
OpenSource Cardiology@opensourcecards·Oct 28

🆕 in OpenSource: Cardiology ACACIA-HCM After ODYSSEY-HCM: Different Verdicts, Similar Signals One myosin-inhibitor trial in nonobstructive HCM was positive and the other was not, but the placebo-corrected effects were close: KCCQ-CSS • ODYSSEY-HCM (mavacamten): +2.7 points (95% CI −0.1 to 5.6; p=0.06) • ACACIA-HCM (aficamten): +3.0 points (95% CI 0.5 to 5.5; p=0.02) Peak VO₂ • ODYSSEY-HCM: +0.47 mL/kg/min (95% CI −0.03 to 0.98; p=0.07) • ACACIA-HCM: +0.67 mL/kg/min (95% CI 0.22 to 1.11; p=0.003) Both trials assumed a 5-point KCCQ-CSS effect, larger than either one observed. @AlbertoAimo90, @PanicellaG and @IacopoOlivotto show the contrast is sharper in the statistical verdict than in the observed efficacy. Their reading is a real but heterogeneous benefit: modest on average, potentially meaningful in selected patients, and offset by a need for structured LVEF monitoring. opensourcecardiology.org/doi… Free to read, no paywalls

Post attachment
OpenSource Cardiology avatar
OpenSource Cardiology@opensourcecards·Oct 26

🆕 in OpenSource: Cardiology Can septal myectomy for obstructive HCM be done safely and effectively outside a high-volume center? 97% of high-volume centers are in large metropolitan areas. At LVHN, one surgeon performed 146 septal myectomies from 2006 to 2023 for patients living a median of 27 miles away. Outcomes compared favorably with national series. The authors’ takeaway: at lower-volume centers, concentrating septal myectomy in a single operator may help build and keep expertise, and bring HCM surgery closer to home. opensourcecardiology.org/doi… Free to read, no paywalls @lvhnsm

Post attachment
OpenSource Cardiology avatar
OpenSource Cardiology@opensourcecards·Oct 22

🆕 in OpenSource: Cardiology Your patient has an LVEF of 42% and late gadolinium enhancement on CMR. Should scar alone earn them a primary-prevention ICD? CMR GUIDE was the first randomized test of that question. A new Critical Appraisal from Mayo Clinic argues the answer is "not yet." • The primary endpoint was neutral: HR 0.76 (95% CI 0.37–1.58)
• Sudden death fell (HR 0.26), but total mortality didn't move: 11.1% vs 11.0%
• The scar-selected patients were lower risk than expected: about 1.1%/yr sudden death in the control arm vs 4%/yr projected
• The ICD arm had more device complications and worse quality of life The authors' verdict: on current evidence, scar alone should not yet prompt a primary-prevention ICD. The under-70 subgroup (3.3% vs 10.0%, HR 0.28) is worth pursuing but remains hypothesis-generating. opensourcecardiology.org/doi… 
Free to read, no paywalls @ramziw_ @tamarappoo

Post attachment
OpenSource Cardiology avatar
⟳ OpenSource Cardiology retweeted
OpenSource Cardiology@opensourcecards·Oct 5

🆕 in OpenSource: Cardiology Can IV digoxin loading help get low-output HFrEF patients off inotropes? Cardiac glycosides are the only oral agents with positive inotropic effects. Yet guidelines don't address their use in acutely decompensated HF or cardiogenic shock. Research letter: Hemodynamic Impact with Intravenous Digoxin Loading in Low Output Heart Failure This single-center HF ICU series reviewed 10 consecutive patients with PA catheters and Fick CI <2.2 L/min/m². Each received IV digoxin 0.5 mg, then 0.25 mg at 6 hours and 0.25 mg 6 hours later. Four were on stable dobutamine or milrinone, with the aim of weaning. At 24 hours: • Median cardiac index 1.45 → 2.70 L/min/m² (p=0.002) • All 4 weaned off IV inotropes, with no decrement in CI or SvO₂ • No significant atrial or ventricular tachyarrhythmia or bradyarrhythmia during the ICU stay The authors' read: IV digoxin loading may have contributed to the rapid CI improvement and may help facilitate inotrope weaning. The series is small, mostly young and uncontrolled, and concurrent vasodilators and diuretics also affected the hemodynamics, so a randomized trial is needed. By @maz_hanna, Rajakrishnan Vijayakrishnan, Rodolfo Benatti, @ChonyAlbertMD, @WilsonTangMD, @NutritionHF, Guilherme Oliveira & @rcstarling opensourcecardiology.org/doi… Free to read, no paywalls

Post attachment
OpenSource Cardiology avatar
OpenSource Cardiology@opensourcecards·Oct 20

🆕 in OpenSource: Cardiology An infant with pulmonary vein stenosis gets an Onyx stent. Even at maximal dilation, the stent will eventually be too small for the vessel. Can it be intentionally fractured later? On the bench, Chelsea Miller, MD, and Michael Shorofsky, MD (@mjshorofsky), of the University of Virginia found that 20 of 21 Resolute Onyx and Onyx Frontier stents (2.0–5.0 mm) demonstrated: • Complete fracture on 6–10 mm high-pressure balloons, median pressure 25 atm • Most fractured linearly (16/20). That is the desired pattern, because it allows complete relief of obstruction and straightforward placement of a larger stent • Smaller stents needed higher balloon-to-stent ratios: 3 for 2 mm stents vs 1.8–2 for 5 mm stents • Only one stent, a 3.5 mm, napkin-ringed and never fractured In vivo, the balloon needed for fracture may be too large to inflate safely in a small vessel. The authors stress that serial dilation remains the clinical standard. opensourcecardiology.org/doi… Free to read, no paywalls

Post attachment
OpenSource Cardiology avatar
OpenSource Cardiology@opensourcecards·Oct 15

When Recognition Outpaces Access: How Treatment Gaps in Resource-Limited Settings Shape ATTR-CM Diagnosis This essay by @Carlos_Penate6 argues that in countries where treatment is out of reach in ATTR-CM, disease recognition falters. Increased access is needed in developing countries to improve patient outcomes. opensourcecardiology.org/doi…

1:16